Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Drug Eruptions
  • Neoplasms

abstract

  • We found that pembrolizumab and nivolumab are both associated with dermatologic AEs, primarily low-grade rash, pruritus, and vitiligo, which are reminiscent of those seen with ipilimumab. Knowledge of these findings is critical for optimal care, maintaining dose intensity, and health-related quality of life in cancer patients receiving PD-1 inhibitors.

publication date

  • June 2016

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4998047

Digital Object Identifier (DOI)

  • 10.1016/j.ejca.2016.02.010

PubMed ID

  • 27043866

Additional Document Info

start page

  • 12

end page

  • 25

volume

  • 60